Budget guide · both medications
Affordable GLP-1 providers, 2026
‘Affordable’ means nothing without a number attached, so this page answers three concrete budgets — about $150, $250 and $450 a month — with the programs that genuinely fit each one today, the FDA-approved options at every level, and the 12-month totals that decide whether a price is actually sustainable.
Three budgets, three honest answers
Around $150 a month. This budget buys semaglutide, not tirzepatide: Oak Longevity at $133 month-to-month, NexLife at $139 promotional ($119 on the twelve-month plan), Yucca at $146, OrderlyMeds at $149 — and on the FDA-approved side, oral Wegovy tablets from $149 at NovoCare and the $199 two-fill Wegovy pen introduction. No rankable tirzepatide program exists at this level; the $133 tirzepatide ads you'll see are start-only prices with no published maintenance figure.
Around $250 a month. Now tirzepatide opens up: NexLife at $169 (promotional) with a standard card at $215, and Yucca's promo-free $258 right behind. On semaglutide this budget clears almost the whole compounded market and the $349 NovoCare pen sits just above it.
Around $450 a month. This is FDA-approved territory: LillyDirect Zepbound at $449 for every maintenance dose, NovoCare Wegovy at $349, both with no membership and no lock. At this budget the case for compounded thins to preference, and platform bundles that resell the same brand products underneath a $149 membership — Hims at ~$548 all-in, Ro at ~$598 cash — need their service layer to justify the spread.
Affordability is a 12-month number
A year of the cheapest rankable tirzepatide currently totals $1,668 (NexLife's prepaid twelve-month plan) against $3,096 for Yucca billed monthly and $5,388 for brand Zepbound at maintenance; a year of semaglutide runs $1,428 on NexLife's twelve-month plan against $4,188 at NovoCare. Prepaid terms cut the monthly rate but concentrate risk — if the program, or the legal ground under compounding, shifts mid-term, refund rights follow the provider's terms, not your expectations. Our methodology prices commitment as a cost for exactly that reason.
Questions people ask
What's the cheapest way to be on a GLP-1 for a full year?
On today's records: about $1,188 for semaglutide on the lowest twelve-month equivalent plans (bmiMD, HealthRX, or Trimi at $99/mo, though Trimi bills as a single $1,188 upfront payment) or $1,548 month-to-month at bmiMD ($129/mo); about $1,668 for tirzepatide (NexLife's twelve-month plan at $139 a month) against $3,096 for a year of Yucca and $5,388 for a year of brand Zepbound at maintenance. Prepaid figures carry commitment risk the monthly figures don't.
Is there any FDA-approved GLP-1 under $200 a month?
Yes: oral Wegovy tablets from $149 a month at NovoCare (the 4 mg tier holds that price through August 31, 2026, then $199), and the Wegovy pen's $199 new-patient introductory price on the first two starter-dose fills through December 31, 2026. The durable pen price is $349.
Does insurance ever make brand cheaper than compounded?
Routinely. A covered commercial patient with a manufacturer savings card can pay as little as $25 a month for Wegovy or Zepbound — below every compounded program in existence — which is why Ro's insurance concierge is a price strategy, not a luxury. Medicare beneficiaries got a separate pathway in July 2026 with the $50-a-month GLP-1 coverage bridge for qualifying patients.
Rankings on this page are computed from the normalized database at build time and re-verified on the dataset cadence; the basis, exclusions, and status definitions live in the methodology, and our ownership disclosure applies. Nothing here is medical advice.